Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAM3R: Durvalumab with Chemotherapy in Advanced Pleural Mesothelioma
NCT04334759Phase 3Completed
- Sponsor
- PrECOG
- Start
- Feb 2021
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 3
01
Overview
A Phase 3 trial of durvalumab in pleural mesothelioma, sponsored by PrECOG. Started Feb 2021; status: completed.
02
Drugs
durvalumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NCT04334759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04334759.